Featured PodcastPodcast Highlights

New Developments in Tetracycline-Class Antibiotics

By December 21, 2020March 18th, 2021No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

New Developments in Tetracycline-class Antibiotics

Dr. Christopher Bunick & Dr. Adam Friedman

 

Tetracycline antibiotics are like the Snickers of dermatology. Instead of “Hungry? Grab a Snickers,” “Acne? Grab a tetracycline…” for months even though this goes against clinical guidelines and concerns regarding antimicrobial resistance (woof, thats a mouthful for a slogan). Like a Snickers, they fulfill a need, they’re good for a whole lot, but too much, not so good. We have seen some evolution in maximizing the clinical benefits of our therapeutic Snickers, such as subantimicrobial dosing, but more innovation is needed to get the most anti-inflammatory bang for our buck. Enter the concept of narrow spectrum antibiotics and sarecycline.

 Join host Dr. Adam Friedman on an investigative journey detailing how antibiotic structure and function can meet to yield novel properties with Dr. Chris Bunick, Associate Professor of Dermatology at Yale School of Medicine and captain of crystallography and cryo-electron microscopy. Hear first hand how a simple idea morphed into a groundbreaking program. Complete your understanding of how antibiotics can be anti-inflammatory. Love the new narrow spectrum lexicon (or try at least).

Listen Now
This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.
Learning Objectives
Upon completion of this podcast, learners should be able to:
  • Summarize the mechanism of action of tetracycline antibiotics and their role in acne
  • Define narrow spectrum antibiotic, and understand the clinical translation.

Disclosures

 

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Christopher Bunick, MD, PhD – Grant/Research: Almirall, Consultant: Almirall, Speakers’ Bureau: Almirall

You May Also Like

From Rags to Itches: The Evolution of Topical and Systemic Options for Pruritus

| Featured Articles, Featured Podcast, Podcast Highlights, The Latest | No Comments
Featured Podcast Life's an itch sometimes….am I right? Pruritus can pick apart the fabric of one's life as both a symptom of a primary skin disease or even as a…
Even in a world of exponentially expanding systemic options both on and off label, one fact remains: topical therapy is ALWAYS on the menu. With an unprecedented array of nonsteroidal options, understanding the underpinnings to both use them for their intended purpose, but even more fun, OOOOOOFFFFFF LLLLLLAAAAABBBBEEEELLLL (clearly a fan of off label), is paramount to patient outcomes. Be not overwhelmed I say, as the bench to bedside badass Dr. Christopher Bunick is here for all your on and off label needs. Take a break from the typical Tuesday with a topical translational deep dive into the tantalizing options as host Dr. Adam Friedman tees off with Dr. Bunick for what is certain to be a “tough” (as the kids say) podcast.

Touching on Tailored Topical for Tons of Tough Treatment Tchallenges

| Featured Articles, Featured Podcast, Podcast Highlights, The Latest | No Comments
Featured Podcast Even in a world of exponentially expanding systemic options both on and off label, one fact remains: topical therapy is ALWAYS on the menu. With an unprecedented array…
What a time to be a psoriasis patient, decades into the golden age of management strategies. With an embarrassment of treatment riches, all patients are clear right? Slow your roll you say? The paradigm shift has occurred and for many of our established patients it’s now about cleaning up the biologic leftovers, especially when located on far reaching and sensitive sites. How to do so? So glad you asked, as we are so fortunate Dr. Peter Lio, clinical assistant professor of dermatology and pediatrics at Northwestern, joined host Dr. Adam Friedman to provide his experiences to pick apart the NYC diner menu of topical option add-ons to our powerful buffet of advanced systemics. Make sure to come hungry!

Pspecial Psite Psoriasis Pearls: Picking the Right Combo Meal for your Patients

| Featured Articles, Featured Podcast, Podcast Highlights, Psoriasis, The Latest | No Comments
Featured Podcast What a time to be a psoriasis patient, decades into the golden age of management strategies. With an embarrassment of treatment riches, all patients are clear right? Slow…

Leave a Reply